Exclusive: Pfizer to invest $25M into tiny UK biotech with epigenetics approach to cancer

Cam­bridge, UK-based start­up Cell­Cen­tric is re­ceiv­ing $25 mil­lion to fin­ish on­go­ing clin­i­cal stud­ies and get some ex­tra run­way in the form of a cash in­fu­sion from one of the world’s largest phar­mas.

Pfiz­er is giv­ing Cell­Cen­tric the funds as a strate­gic in­vest­ment, Cell­Cen­tric CEO Will West told End­points News, get­ting ac­cess to what he said would be the “in­side seat” as more da­ta ma­te­ri­al­ize.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN